Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIGMAR1 | Q99720 | 9/20 | 0.60 |
| ▸ | EBP | Q15125 | 2/20 | 0.60 |
| ▸ | CCR3 | P51677 | 2/20 | 0.54 |
| ▸ | KCNA3 | P22001 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5237846 | 0.95 | SIGMAR1 (0.60) | SIGMAR1EBPCCR3KCNA3 | |
| SCHEMBL14431859 | 0.92 | CCR3 (0.54) | SIGMAR1EBPCCR3KCNA3 | |
| SCHEMBL11932001 | 0.92 | SIGMAR1 (0.52) | SIGMAR1EBPCCR3 | |
| SCHEMBL21023241 | 0.92 | SIGMAR1 (0.52) | SIGMAR1EBPCCR3 | |
| SCHEMBL5240018 | 0.90 | RAB9A (0.52) | SIGMAR1EBPCCR3KCNA3 | |
| SCHEMBL14431920 | 0.89 | RAB9A (0.58) | SIGMAR1EBPCCR3KCNA3 | |
| SCHEMBL14431854 | 0.89 | SIGMAR1 (0.51) | SIGMAR1EBPCCR3KCNA3 | |
| SCHEMBL5750440 | 0.86 | CCR3 (0.52) | SIGMAR1EBPCCR3KCNA3 | |
| SCHEMBL5754473 | 0.86 | SIGMAR1 (0.49) | SIGMAR1EBPCCR3KCNA3 | |
| SCHEMBL5752928 | 0.86 | SIGMAR1 (0.50) | SIGMAR1EBPCCR3KCNA3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1818326-A1 | Nitrogen-containing heterocyclic compounds and pharmaceutical composition containing the compounds | Eisai R&D Management Co., Ltd. (JP) | 2007-08-15 | — | — | EP | disclosed |
| EP-1818326-A1 | Nitrogen-containing heterocyclic compounds and pharmaceutical composition containing the compounds | Eisai R&D Management Co., Ltd. (JP) | 2007-08-15 | — | — | EP | disclosed |
| US-20060084658-A1 | Nitrogen-containing cyclic compound and pharmaceutical composition containing the compound | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2006-04-20 | — | — | US | disclosed |
| US-20040220193-A1 | Nitrogen-containing cyclic compound and pharmaceutical composition containing the compound | EISAI CO., LTD. | 2004-11-04 | — | — | US | disclosed |
| EP-1254895-A1 | NITROGENOUS CYCLIC COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME | Eisai Co., Ltd. (JP) | 2002-11-06 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040220193-A1 | Nitrogen-containing cyclic compound and pharmaceutical composition containing the compound | CACNA1D, CACNA1B, CACNA1E | SIGMAR1 143/4885EBP 560/4885CCR3 1951/4885 |
| US-20060084658-A1 | Nitrogen-containing cyclic compound and pharmaceutical composition containing the compound | CACNA1B, CACNA1E, CACNA1D | SIGMAR1 133/4885EBP 964/4885CCR3 1977/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.